Amneal Pharmaceuticals Inc (AMRX)

$13.26 +0.27 (2.08%)
Market Cap 3.98B
Revenue (ttm) 2.79B
Net Income (ttm) -116.89M
EPS (ttm) N/A
PE Ratio 18.81
Forward PE 14.65
Profit Margin -4.18%
Debt to Equity Ratio -23.41
Volume 1,515,200
Avg Vol 1,859,894
Day's Range N/A - N/A
Shares Out 314.36M
Stochastic %K 89%
Beta 1.34
Analysts Strong Sell
Price Target $14.00

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 947 3120
Fax: 908 947 3146
Address:
400 Crossing Boulevard, 3rd Floor, Bridgewater, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 10:23 PM
$AMRX RSI: 67.58, MACD: 0.3329 Vol: 0.33, MA20: 12.36, MA50: 11.64 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Merlintrader
Merlintrader Dec. 26 at 8:49 PM
$AMRX https://www.merlintrader.com/amrx-amneal/
0 · Reply
ActuaryAlpha
ActuaryAlpha Dec. 25 at 7:57 AM
$AMRX Market tolerance narrows as uncertainty lingers, amid evolving funding conditions and shifting competitive responses. Absent traction, patience will erode.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:36 PM
$AMRX (+0.9% pre) Amneal stock rises after FDA approves two denosumab biosimilars https://ooc.bz/l/88246
0 · Reply
islandpunk
islandpunk Dec. 23 at 2:43 AM
$AMRX only ~6% of shares are held by retail. 46% held by insiders 47-48% held by institutions Institutional holders include: Vanguard Group Inc. ~5.72 % BlackRock, Inc. ~4.49 % Rubric Capital Management LP ~3.93 % TPG GP A, LLC ~3.93 % Citadel Advisors LLC ~1.82 % Dimensional Fund Advisors LP ~1.73 % Nantahala Capital Management LLC ~1.35 % Geode Capital Management, LLC ~1.29 % State Street Corp ~1.27 % Neuberger Berman Group LLC ~1.18 %
0 · Reply
Bombay55
Bombay55 Dec. 22 at 10:43 PM
$AMRX so a P/E of 776? wow
0 · Reply
dixiebull
dixiebull Dec. 22 at 9:39 PM
$TE slow push to 7.38 afterhours, see if 7.50 breaks for 8, want 7.25 to hold $AMRX FDA approval pushed to 13.12, see if 12.75 holds on a dip for 13.50 and 15 $OCUL testing 13 here, if 13 breaks it can get 13.50/14 $CETX afterhours run to 3.77, see if 3.50 holds for 4 and 4.50 to 5 $IONQ hit 55.60 with a strong market, see if 53.50 holds for 56.50 and 58
0 · Reply
notreload_ai
notreload_ai Dec. 22 at 9:38 PM
$AMRX , $AMGN ... Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment. https://notreload.xyz/fda-approves-amneals-denosumab-biosimilars-for-bone-health/
0 · Reply
islandpunk
islandpunk Dec. 22 at 9:05 PM
$AMRX https://www.stocktitan.net/news/AMRX/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-qwyo52ygz417.html
0 · Reply
Estimize
Estimize Dec. 22 at 2:00 PM
Wall St is expecting 0.18 EPS for $AMRX Q4 [Reporting 03/04 BMO] http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_co
0 · Reply
Latest News on AMRX
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Dec 22, 2025, 4:01 PM EST - 16 days ago

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Dec 17, 2025, 11:01 PM EST - 21 days ago

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Dec 9, 2025, 4:01 PM EST - 4 weeks ago

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease

Dec 5, 2025, 8:00 AM EST - 4 weeks ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Dec 2, 2025, 8:00 AM EST - 5 weeks ago

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Amneal to Participate in Upcoming Investor Conferences

Dec 2, 2025, 8:00 AM EST - 5 weeks ago

Amneal to Participate in Upcoming Investor Conferences

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Dec 1, 2025, 4:01 PM EST - 5 weeks ago

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Amneal Receives U.S. FDA Approval for Iohexol Injection

Nov 13, 2025, 4:01 PM EST - 7 weeks ago

Amneal Receives U.S. FDA Approval for Iohexol Injection

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:56 PM EDT - 2 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Amneal Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 AM EDT - 2 months ago

Amneal Reports Third Quarter 2025 Financial Results

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Oct 29, 2025, 4:05 PM EDT - 2 months ago

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Sep 30, 2025, 4:05 PM EDT - 3 months ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Sep 26, 2025, 8:00 AM EDT - 3 months ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Sep 23, 2025, 8:00 AM EDT - 3 months ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Sep 11, 2025, 8:00 AM EDT - 4 months ago

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing

Sep 11, 2025, 7:23 AM EDT - 4 months ago

Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Sep 4, 2025, 4:01 PM EDT - 4 months ago

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:56 PM EDT - 5 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Amneal Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 6:00 AM EDT - 5 months ago

Amneal Reports Second Quarter 2025 Financial Results

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Jul 21, 2025, 7:39 AM EDT - 6 months ago

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Jul 21, 2025, 7:38 AM EDT - 6 months ago

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Jul 18, 2025, 7:00 AM EDT - 6 months ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Jun 12, 2025, 8:00 AM EDT - 7 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 7 months ago

Amneal to Participate at Upcoming Investor Conferences in June

US FDA approves Amneal's migraine treatment

May 15, 2025, 8:16 AM EDT - 8 months ago

US FDA approves Amneal's migraine treatment

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 15, 2025, 8:00 AM EDT - 8 months ago

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 8, 2025, 7:00 AM EDT - 8 months ago

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

May 2, 2025, 11:32 AM EDT - 8 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

Amneal Reports First Quarter 2025 Financial Results

May 2, 2025, 6:00 AM EDT - 8 months ago

Amneal Reports First Quarter 2025 Financial Results

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Apr 11, 2025, 8:00 AM EDT - 9 months ago

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 8, 2025, 4:05 PM EDT - 9 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Apr 7, 2025, 8:00 AM EDT - 9 months ago

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Apr 3, 2025, 8:00 AM EDT - 10 months ago

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Apr 1, 2025, 8:00 AM EDT - 10 months ago

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 19, 2025, 3:14 PM EDT - 10 months ago

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Amneal to Participate at Upcoming Investor Conference

Mar 10, 2025, 4:05 PM EDT - 10 months ago

Amneal to Participate at Upcoming Investor Conference

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Mar 3, 2025, 4:05 PM EST - 11 months ago

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 2:20 PM EST - 11 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 6:00 AM EST - 11 months ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Feb 24, 2025, 1:42 PM EST - 11 months ago

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Feb 19, 2025, 8:00 AM EST - 11 months ago

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Jan 29, 2025, 8:30 AM EST - 1 year ago

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Jan 23, 2025, 8:00 AM EST - 1 year ago

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Amneal to Participate at Upcoming Investor Conferences

Dec 4, 2024, 8:00 AM EST - 1 year ago

Amneal to Participate at Upcoming Investor Conferences

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Nov 21, 2024, 4:05 PM EST - 1 year ago

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 3:27 PM EST - 1 year ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 10:23 PM
$AMRX RSI: 67.58, MACD: 0.3329 Vol: 0.33, MA20: 12.36, MA50: 11.64 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Merlintrader
Merlintrader Dec. 26 at 8:49 PM
$AMRX https://www.merlintrader.com/amrx-amneal/
0 · Reply
ActuaryAlpha
ActuaryAlpha Dec. 25 at 7:57 AM
$AMRX Market tolerance narrows as uncertainty lingers, amid evolving funding conditions and shifting competitive responses. Absent traction, patience will erode.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:36 PM
$AMRX (+0.9% pre) Amneal stock rises after FDA approves two denosumab biosimilars https://ooc.bz/l/88246
0 · Reply
islandpunk
islandpunk Dec. 23 at 2:43 AM
$AMRX only ~6% of shares are held by retail. 46% held by insiders 47-48% held by institutions Institutional holders include: Vanguard Group Inc. ~5.72 % BlackRock, Inc. ~4.49 % Rubric Capital Management LP ~3.93 % TPG GP A, LLC ~3.93 % Citadel Advisors LLC ~1.82 % Dimensional Fund Advisors LP ~1.73 % Nantahala Capital Management LLC ~1.35 % Geode Capital Management, LLC ~1.29 % State Street Corp ~1.27 % Neuberger Berman Group LLC ~1.18 %
0 · Reply
Bombay55
Bombay55 Dec. 22 at 10:43 PM
$AMRX so a P/E of 776? wow
0 · Reply
dixiebull
dixiebull Dec. 22 at 9:39 PM
$TE slow push to 7.38 afterhours, see if 7.50 breaks for 8, want 7.25 to hold $AMRX FDA approval pushed to 13.12, see if 12.75 holds on a dip for 13.50 and 15 $OCUL testing 13 here, if 13 breaks it can get 13.50/14 $CETX afterhours run to 3.77, see if 3.50 holds for 4 and 4.50 to 5 $IONQ hit 55.60 with a strong market, see if 53.50 holds for 56.50 and 58
0 · Reply
notreload_ai
notreload_ai Dec. 22 at 9:38 PM
$AMRX , $AMGN ... Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment. https://notreload.xyz/fda-approves-amneals-denosumab-biosimilars-for-bone-health/
0 · Reply
islandpunk
islandpunk Dec. 22 at 9:05 PM
$AMRX https://www.stocktitan.net/news/AMRX/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-qwyo52ygz417.html
0 · Reply
Estimize
Estimize Dec. 22 at 2:00 PM
Wall St is expecting 0.18 EPS for $AMRX Q4 [Reporting 03/04 BMO] http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_co
0 · Reply
Digger75
Digger75 Dec. 19 at 11:57 AM
$AMRX
0 · Reply
dixiebull
dixiebull Dec. 18 at 10:00 PM
$MRNA going on all the articles about measles and new flu, see if 31 holds for 32.50 and 33 $AMRX nice push to test 13, see if 12.50 holds for a move to 13 and 13.50 to 14 $MGRT ran to test 10 res twice today, se eif 7.35 holds for a move back to 10 $AFJK guided this from first halt to 82, now pulling back, see if 40 holds or it could pull to 30 $ISSC nice early trade to 15.40, see if this 14 holds now for a break of 15 to 15.50 and 16
1 · Reply
lenten
lenten Dec. 18 at 9:40 PM
$SPY $AMRX $DJT $RIVN $ISSC
0 · Reply
GSP
GSP Dec. 18 at 9:36 PM
$SPY $AMRX $DJT $RIVN $ISSC
0 · Reply
tamperson
tamperson Dec. 12 at 12:30 AM
$AMRX Jump in, under accumulation. Good / increasing daily volume and After-Hour volume. MM’s keeping it at $12 to $12.25 allowing friends to take a healthy position before next leg up.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 5:43 PM
$AMRX Current Stock Price: $11.97 Contracts to trade: $10 AMRX Dec 19 2025 Call Entry: $1.20 Exit: $2.28 ROI: 90% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
notreload_ai
notreload_ai Dec. 9 at 9:25 PM
The FDA has approved $AMRX new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings. https://notreload.xyz/fda-oks-amneal-epinephrine-vials-for-emergency-care/
0 · Reply
G101SPM
G101SPM Dec. 9 at 9:10 PM
$AMRX 11.97 bid Holding long position https://stocktwits.com/G101SPM/message/637839332 BRIEF: Co announces that the FDA has approved the company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
1 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:20 PM
Barclays has updated their rating for Amneal Pharmaceuticals ( $AMRX ) to Overweight with a price target of 15.
0 · Reply
Digger75
Digger75 Dec. 3 at 2:18 PM
$AMRX
0 · Reply
G101SPM
G101SPM Dec. 1 at 9:07 PM
$AMRX $12.35 bid. Holding long position at $8.20 https://stocktwits.com/G101SPM/message/583493657 CHAMNGE EXIT TO $19.00 (long term) FROM $16.00. BRIEF: Today announced the U.S. Food and Drug Administration (FDA) has approved the Company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.
0 · Reply
ZacksResearch
ZacksResearch Nov. 28 at 4:02 PM
$ANIP vs. $AMRX — one of these niche drugmakers is shaping up as the clear momentum play. ANI Pharmaceuticals is riding rare-disease strength, with surging Cortrophin Gel sales giving it the stronger growth profile compared to its more diversified rival. Full breakdown here 👉 https://www.zacks.com/stock/news/2797189/anip-vs-amrx-which-niche-drugmaker-is-the-better-pick?cid=sm-stocktwits-2-2797189-teaser-22735&ADID=SYND_STOCKTWITS_TWEET_2_2797189_TEASER_22735
0 · Reply